BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 32483443)

  • 1. BBB-penetrating codelivery liposomes treat brain metastasis of non-small cell lung cancer with EGFR
    Yin W; Zhao Y; Kang X; Zhao P; Fu X; Mo X; Wang Y; Huang Y
    Theranostics; 2020; 10(14):6122-6135. PubMed ID: 32483443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reprogramming Tumor-Associated Macrophages To Reverse EGFR
    Peng H; Chen B; Huang W; Tang Y; Jiang Y; Zhang W; Huang Y
    Nano Lett; 2017 Dec; 17(12):7684-7690. PubMed ID: 29160717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Remodeling Tumor-Associated Macrophages and Neovascularization Overcomes EGFR
    Yin W; Yu X; Kang X; Zhao Y; Zhao P; Jin H; Fu X; Wan Y; Peng C; Huang Y
    Small; 2018 Nov; 14(47):e1802372. PubMed ID: 30307695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 5. Tumor immune microenvironment and nivolumab efficacy in EGFR mutation-positive non-small-cell lung cancer based on T790M status after disease progression during EGFR-TKI treatment.
    Haratani K; Hayashi H; Tanaka T; Kaneda H; Togashi Y; Sakai K; Hayashi K; Tomida S; Chiba Y; Yonesaka K; Nonagase Y; Takahama T; Tanizaki J; Tanaka K; Yoshida T; Tanimura K; Takeda M; Yoshioka H; Ishida T; Mitsudomi T; Nishio K; Nakagawa K
    Ann Oncol; 2017 Jul; 28(7):1532-1539. PubMed ID: 28407039
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The canonical TGF-β/Smad signalling pathway is involved in PD-L1-induced primary resistance to EGFR-TKIs in EGFR-mutant non-small-cell lung cancer.
    Zhang Y; Zeng Y; Liu T; Du W; Zhu J; Liu Z; Huang JA
    Respir Res; 2019 Jul; 20(1):164. PubMed ID: 31331328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tyrosine phosphoproteomics identifies both codrivers and cotargeting strategies for T790M-related EGFR-TKI resistance in non-small cell lung cancer.
    Yoshida T; Zhang G; Smith MA; Lopez AS; Bai Y; Li J; Fang B; Koomen J; Rawal B; Fisher KJ; Chen YA; Kitano M; Morita Y; Yamaguchi H; Shibata K; Okabe T; Okamoto I; Nakagawa K; Haura EB
    Clin Cancer Res; 2014 Aug; 20(15):4059-4074. PubMed ID: 24919575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced anticancer effect of the combination of BIBW2992 and thymidylate synthase-targeted agents in non-small cell lung cancer with the T790M mutation of epidermal growth factor receptor.
    Takezawa K; Okamoto I; Tanizaki J; Kuwata K; Yamaguchi H; Fukuoka M; Nishio K; Nakagawa K
    Mol Cancer Ther; 2010 Jun; 9(6):1647-56. PubMed ID: 20530710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non-Small Cell Lung Cancer.
    Yun J; Hong MH; Kim SY; Park CW; Kim S; Yun MR; Kang HN; Pyo KH; Lee SS; Koh JS; Song HJ; Kim DK; Lee YS; Oh SW; Choi S; Kim HR; Cho BC
    Clin Cancer Res; 2019 Apr; 25(8):2575-2587. PubMed ID: 30670498
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer by Inducing Epidermal Growth Factor Receptor Degradation via Methionine 790 Oxidation.
    Leung EL; Fan XX; Wong MP; Jiang ZH; Liu ZQ; Yao XJ; Lu LL; Zhou YL; Yau LF; Tin VP; Liu L
    Antioxid Redox Signal; 2016 Feb; 24(5):263-79. PubMed ID: 26528827
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3.
    Yue J; Lv D; Wang C; Li L; Zhao Q; Chen H; Xu L
    Oncogene; 2018 Aug; 37(31):4300-4312. PubMed ID: 29717264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGFR-TKI down-regulates PD-L1 in EGFR mutant NSCLC through inhibiting NF-κB.
    Lin K; Cheng J; Yang T; Li Y; Zhu B
    Biochem Biophys Res Commun; 2015 Jul 17-24; 463(1-2):95-101. PubMed ID: 25998384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T790M-Selective EGFR-TKI Combined with Dasatinib as an Optimal Strategy for Overcoming EGFR-TKI Resistance in T790M-Positive Non-Small Cell Lung Cancer.
    Watanabe S; Yoshida T; Kawakami H; Takegawa N; Tanizaki J; Hayashi H; Takeda M; Yonesaka K; Tsurutani J; Nakagawa K
    Mol Cancer Ther; 2017 Nov; 16(11):2563-2571. PubMed ID: 28839001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring the Response of PD-L1 Expression to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Nonsmall-Cell Lung Cancer Xenografts by Immuno-PET Imaging.
    Li D; Zou S; Cheng S; Song S; Wang P; Zhu X
    Mol Pharm; 2019 Aug; 16(8):3469-3476. PubMed ID: 31283253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of EGFR-TKIs combined with PD-L1 antibody on the lung tissue of EGFR-driven tumor-bearing mice.
    Jia Y; Zhao S; Jiang T; Li X; Zhao C; Liu Y; Han R; Qiao M; Liu S; Su C; Ren S; Zhou C
    Lung Cancer; 2019 Nov; 137():85-93. PubMed ID: 31563735
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TAZ sensitizes EGFR wild-type non-small-cell lung cancer to gefitinib by promoting amphiregulin transcription.
    Yuan W; Xu W; Li Y; Jiang W; Li Y; Huang Q; Chen B; Wu S; Wang Y; Song W; Zhao W; Wu J
    Cell Death Dis; 2019 Mar; 10(4):283. PubMed ID: 30911072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced Sensitivity of Nonsmall Cell Lung Cancer with Acquired Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors to Phenformin: The Roles of a Metabolic Shift to Oxidative Phosphorylation and Redox Balance.
    Kim S; Im JH; Kim WK; Choi YJ; Lee JY; Kim SK; Kim SJ; Kwon SW; Kang KW
    Oxid Med Cell Longev; 2021; 2021():5428364. PubMed ID: 34367462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Randomized Phase II Study Comparing Nivolumab With Carboplatin-Pemetrexed for Patients With EGFR Mutation-Positive Nonsquamous Non-Small-Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation: Rationale and Protocol Design for the WJOG8515L Study.
    Hayashi H; Chiba Y; Sakai K; Fujita T; Yoshioka H; Sakai D; Kitagawa C; Naito T; Takeda K; Okamoto I; Mitsudomi T; Kawakami Y; Nishio K; Nakamura S; Yamamoto N; Nakagawa K
    Clin Lung Cancer; 2017 Nov; 18(6):719-723. PubMed ID: 28623122
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apatinib enhances antitumour activity of EGFR-TKIs in non-small cell lung cancer with EGFR-TKI resistance.
    Li F; Zhu T; Cao B; Wang J; Liang L
    Eur J Cancer; 2017 Oct; 84():184-192. PubMed ID: 28822888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations.
    Lin YT; Chen JS; Liao WY; Ho CC; Hsu CL; Yang CY; Chen KY; Lee JH; Lin ZZ; Shih JY; Yang JC; Yu CJ
    Int J Cancer; 2019 Jun; 144(11):2887-2896. PubMed ID: 30485437
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.